VCs PIPE $43.5 Million to Sunesis Pharma
Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) has agreed to raise $43.5 million via a private placement of convertible preferred stock, common stock and common stock warrants. Investors include Bay City Capital, New Enterprise Associates, Alta Partners, Caxton Advantage Life Sciences Fund, Merlin Nexus, Nextech Venture, OpusPoint Partners, Venrock and Vision Capital Advisors.
7 April 2009•5 mins read
